September 11, 2007 - Terumo Interventional Systems announces the launch of its breakthrough Runthrough NS Coronary Guidewire in the U.S. market for use in percutaneous transluminal coronary angioplasties (PTCA), as the company expands its position in the coronary market.

Runthrough NS is designed to provide tip durability, complete torque transfer and enhanced steerability. This coronary guidewire boasts efficiency and reliability.

September 11, 2007 – Improving how healthcare providers follow proven protocols could reduce the risks of subsequent heart problems for heart disease patients, according to a study reported in a cardiovascular surgery supplement of Circulation: Journal of the American Heart Association.

A study of the American Heart Association's Get With The GuidelinesSM (GWTG) database found significant differences in how hospitals carry out many of the association's secondary prevention recommendations.

September 11, 2007 - CellCyte Genetics Corp. has entered into a collaborative research agreement with physician scientists at the Cleveland Clinic Foundation to investigate the presence and regulation of heart receptors involved in stem cell trafficking in normal and diseased human hearts, using CellCyte's proprietary compounds, with the goal of increasing volumes of stem cells delivered.

September 11, 2007 - The Certification Commission for Healthcare Information Technology (CCHIT) and the MITRE Corp. recently announced a collaborative relationship to begin building a testing resource to evaluate compliance of electronic health records (EHRs) and networks with certification criteria for interoperability.

September 11, 2007 - Stereotaxis Inc. said more than 10,000 procedures have been performed using the Stereotaxis system, which utilizes advanced, magnet-guided navigational technology intended to help electrophysiologists and cardiologists treat complex arrhythmias and safely perform other interventional procedures.


iffering approaches for the treatment of coronary bifurcation and ostial lesions (CBOL) continue to feed the debate over which stent designs and stenting techniques are most effective.


According to the Centers for Disease Control and Prevention, more than 70 million Americans currently live with cardiovascular disease, with 700,000 dying from it each year.
In an age where heart disease is responsible for 29 percent of all U.S. deaths, cutting-edge technology and know-how is crucial to today’s cath labs.

Just when drug-eluting stents (DES) were going to revolutionize interventional cardiology, new reports that DES may be associated with increased risk of late-stent thrombosis have many physicians putting the brakes on DES use. Despite this significant bump in the road, stent manufacturers are forging ahead with clinical trials on novel systems and on plans to roll out new DES platforms in 2008.

September 6, 2007 — ProSolv CardioVascular, a FUJIFILM company (ProSolv), announced at the 12th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC) that it has further enhanced its CardioVascular Image and Information Systems (CVIIS) product line with the integration of Corridor4DM (previously known as 4DM-SPECT) capabilities, allowing clinicians to access 4DM review, analysis and quantification tools from any ProSolv CardioVascular workstation.

September 10, 2007 - Four analyses of three-year follow-up data that were presented at the ESC Congress 2007 showed that the CYPHER Sirolimus-eluting Coronary Stent may be considered an appropriate alternative to bypass surgery in patients with blockages in two or more coronary arteries (multivessel disease).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now